Status:
COMPLETED
Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease
Lead Sponsor:
UCB Pharma
Conditions:
Parkinson's Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this trial is to assess whether rotigotine has an effect on the electrical activity of the heart. Moxifloxacin infusion is used as positive control to assess assay sensitivity.
Eligibility Criteria
Inclusion
- Male or female at least 18 years of age
- Advanced-stage idiopathic Parkinson's disease requiring treatment with levodopa.
- Nonchildbearing potential
Exclusion
- Atypical Parkinson's syndrome(s).
- History of pallidotomy, thalamotomy, deep brain stimulation, or fetal tissue transplant.
- Significant tremor or dyskinesias.
- Severe dysfunction of the autonomic nervous system.
- History of transient ischemic attack or stroke within the last 12 months.
- Conduction abnormality or relevant cardiac dysfunction and/or myocardial infarction within last 12 months.
- History or current condition of additional risk factors for Torsade de Pointes (eg, heart failure, hypokalemia), or a family history of long QT syndrome and/or of Torsade de Pointes.
- No stable sinus rhythm: more than 20 ectopics/h.
- Any other clinically relevant ECG abnormality.
- History or current condition of epilepsy and/or seizures.
- History or current condition of atopic or eczematous dermatitis, psoriasis, or another active skin disease.
- History or current condition of symptomatic orthostatic hypotension.
- History or current condition of significant skin hypersensitivity to adhesives or other transdermal products or recent unresolved contact dermatitis.
- History of glucose 6-phosphate dehydrogenase deficiency.
- History of tendonitis or tendon rupture with quinolone antibiotics.
- Renal or hepatic dysfunction.
- Treatment with dopamine agonists, MAO A inhibitors, reserpine, or alpha-methyldopa
- Therapy known to produce a nontrivial prolongation of the QT interval.
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2006
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00292227
Start Date
January 1 2006
End Date
October 1 2006
Last Update
October 27 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Farmovs-Parexel (Pty) Ltd
Bloemfontein, South Africa
2
Qdot, a division of Parexel International DA (Pty) Ltd.
George, South Africa